Novartis AG
NVS
$164.70
$2.031.25%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 17.11% | -18.24% | -15.59% | -15.65% | -19.59% |
| Total Depreciation and Amortization | 3.15% | 147.08% | 124.01% | 107.27% | 88.56% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 20.19% | 338.13% | 483.13% | 322.85% | 411.64% |
| Change in Net Operating Assets | -68.78% | 54.99% | 42.03% | 36.33% | 4.73% |
| Cash from Operations | 8.66% | 31.93% | 37.99% | 38.01% | 21.86% |
| Capital Expenditure | -13.32% | -23.31% | -26.86% | -24.49% | -28.87% |
| Sale of Property, Plant, and Equipment | -84.88% | -70.94% | -76.68% | -56.82% | -63.71% |
| Cash Acquisitions | 27.43% | 39.33% | 69.25% | 0.40% | -12.83% |
| Divestitures | -182.24% | 244.07% | 343.75% | 740.91% | 3,466.67% |
| Other Investing Activities | 85.44% | -44.40% | -1,402.34% | -11.48% | -123.27% |
| Cash from Investing | 35.09% | 6.96% | 34.14% | -6.08% | -234.26% |
| Total Debt Issued | -15.69% | -82.11% | 5.07% | 310.19% | 411.84% |
| Total Debt Repaid | -20.44% | 26.57% | 39.18% | -30.14% | -1.09% |
| Issuance of Common Stock | -10.00% | -23.33% | 4.00% | -- | -81.13% |
| Repurchase of Common Stock | -10.57% | -53.76% | -97.39% | -43.40% | 4.50% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -2.54% | -2.54% | -2.54% | -48.84% | -5.09% |
| Other Financing Activities | -42.03% | -645.00% | -110.37% | -104.78% | -105.95% |
| Cash from Financing | -26.61% | -108.98% | -74.83% | -47.71% | 17.76% |
| Foreign Exchange rate Adjustments | 293.29% | 28.41% | 355.42% | 106.02% | -398.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 98.76% | -436.63% | 58.18% | 5.06% | -132.91% |